follow us:
Oncologists on Tuesday hailed the central government's move to exempt three more cancer drugs from customs duty. The three drugs are Trastuzumab deruxtecan (for breast cancer), Osimertinib (lung cancer drug for EGFR mutation), and Durvalumab (for lun